# Physical Interaction Between Retinoic Acid Receptor and Sp1: Mechanism for Induction of Urokinase by Retinoic Acid

By Yasuhiro Suzuki, Jun Shimada, Koichi Shudo, Masatoshi Matsumura, Massimo P. Crippa, and Soichi Kojima

Induction of urokinase plasminogen activator (uPA) by retinoic acid (RA) is the initial event preceding certain subsequent biological changes in vascular endothelial cells. We investigated the molecular mechanism by which RA stimulates the expression of uPA, which lacks a canonical RA receptor (RAR)-responsive element, in bovine and human aortic endothelial cells. Upon stimulation with RA, mRNA levels of RAR $\alpha$  and  $\beta$  transiently increased in parallel with the induction of uPA, and this increase was inhibited by cycloheximide. Results of transient transfection of RAR/RXR cDNAs and experiments using specific agonists and antagonists suggested that uPA induction is dependent upon RAR (initially, RAR $\alpha$ ) with the help of RXR $\alpha$ . Deletion analysis of the uPA promoter suggested that RAR/RXR acts on GC box

ETINOL (VITAMIN A) and its derivatives (retinoids) R exert profound effects on the regulation of cell growth and differentiation, mainly through two families of nuclear receptors, the retinoic acid (RA) receptors (RARs) and the retinoid X receptors (RXRs).<sup>1,2</sup> These receptors are liganddependent transcription factors that bind to cis-acting DNA sequences, called RAR-responsive elements (RAREs) and RXR-responsive elements (RXREs), located in the promoter region of their target genes.1-3 The RAR and RXR gene families are each composed of three subtypes, named  $\alpha$ ,  $\beta$ , and  $\gamma$ . Expression of RARs increases in an autocrine manner immediately after stimulation with RA, because these receptors contain typical RARE sequences.<sup>1-3</sup> RARs bind to the RARE in response to both all-trans-RA (atRA) and 9-cis-RA (9cRA), whereas RXRs bind and activate transcription in response to only 9cRA. To recognize an RARE, RARs usually must form a heterodimer with RXRs under physiological condition.<sup>1,2</sup> Re-

Submitted September 15, 1998; accepted February 8, 1999.

Supported partly by Grant-in-Aids from the Ministry of Education, Science, Sports and Culture (10780395), Grant-in-Aids from Tokyo Biochemical Research Foundation, Grants for "Biodesign Research Program" and "Multibioprobe Research Program" from RIKEN, and The Sumitomo Foundation.

Address reprint requests to Soichi Kojima, PhD, Laboratory of Molecular Cell Sciences, Tsukuba Life Science Center, The Institute of Physical and Chemical Research (RIKEN), Koyadai, Tsukuba, Ibaraki 305-0074, Japan; e-mail: kojima@rtc.riken.go.jp.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1999 by The American Society of Hematology. 0006-4971/99/9312-0027\$3.00/0

region within the uPA promoter. This was further supported by inhibition of Sp1 binding to this region. Coimmunoprecipitation studies, glutathione *S*-transferase pull-down experiment, and mammalian two-hybrid assays suggested a physical interaction between RAR/RXR and Sp1. Furthermore, gel shift studies showed that the binding of Sp1 to the uPA GC box is significantly potentiated in the presence of RARs/ RXRs. Finally, Sp1 and RAR/RXR synergistically enhanced the transactivation activity of the uPA promoter. These results suggest that (1) RA induces RARs mainly via RAR $\alpha$ and that (2) RAR/RXR physically and functionally interact with Sp1, resulting in a potentiation of uPA transcription. © 1999 by The American Society of Hematology.

cent studies have indicated that RARs/RXRs, upon binding to ligands, promote transcription through interaction with coactivators such as SRC-1, GRIP1, p/CIP, and p300/CBP after dissociation from corepressors such as NCoR and SMRT.<sup>4-7</sup> However, not all RA-inducible genes contain RARE sequence(s) within their promoter.

In many cell types, RA enhances the production of plasminogen activator (PA), an enzyme responsible for the conversion of plasminogen to plasmin.<sup>8,9</sup> There are two immunologically distinct PAs, urokinase PA (uPA) and tissue PA (tPA). uPA is thought to be related to tissue remodeling and metastasis, whereas tPA has high affinity for fibrin and mainly participates in vascular thrombolysis.<sup>8,9</sup> In bovine aortic endothelial cells (BAECs) and rat liver stellate cells, RA enhances cellular fibrinolytic levels through rapid stimulation of the expression of uPA and related genes, resulting in the induction of active transforming growth factor- $\beta$  (TGF- $\beta$ ), that subsequently mediates some of the actions of RA in these cells.<sup>10-15</sup>

These sequential changes, induced in BAECs by RA, are initiated by upregulation of the transcription of the uPA gene, which does not contain a canonical RARE sequence. In the present study, we investigated the molecular mechanism of this initial event and found that (1) RA induces RARs expression initially via RAR $\alpha$  and that (2) RARs/RXRs directly interact with Sp1, culminating in the augmented binding of Sp1 to the uPA GC box and in the enhanced transcription of the uPA gene in endothelial cells.

## MATERIALS AND METHODS

*Materials.* Actinomycin D, cycloheximide, atRA, and 9cRA were purchased from Sigma Chemical Co (St Louis, MO). Mithramycin was obtained from Calbiochem (La Jolla, CA). The RAR $\alpha$ -selective retinoid (Am580), pan-RAR-selective retinoid (Ch55), and RAR $\beta$ -selective antagonist (LE135) were synthesized and characterized as described previously.<sup>16-18</sup> The RAR $\beta$ -selective retinoid (CD2019) and RAR $\gamma$ selective retinoid (CD666) were kindly provided by Dr S. Michel (CIRD/GALDERMA, Sophia Antipolis, France).<sup>19,20</sup> The RXR $\alpha$ selective retinoid (Ro25-7386), pan-RXR-selective retinoid (Ro47-5944), and RAR $\alpha$ -selective antagonist (Ro41-5253) were generous gifts from Dr M. Klaus (F. Hoffmann-La Roche, Basel, Switzerland).<sup>21-23</sup> Retinoids were diluted in ethanol and serially diluted into

From the Laboratory of Molecular Cell Sciences, Tsukuba Life Science Center, The Institute of Physical and Chemical Research (RIKEN), Tsukuba, Ibaraki, Japan; the Institute of Applied Biochemistry, University of Tsukuba, Tennoudai, Tsukuba, Ibaraki, Japan; the Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; and the Laboratory of Molecular Genetics, DIBIT-H. S. Raffaele, Milano, Italy.

culture medium to yield a final ethanol concentration of 0.5%. Human Sp1 was obtained from Promega (Madison, WI). RARs-glutathione *S*-transferase (GST) and RXRs-GST fusion proteins were purified from *Escherichia coli* BL21 transformed with the pGEX-6P (Pharmacia Biotech, Uppsala, Sweden) vector containing inserted human RAR and murine RXR cDNAs, respectively. Briefly, after induction by 2 mmol/L isopropyl  $\beta$ -D-thiogalactopyranoside (IPTG) for 4 hours, the cells were disrupted by sonication and the fusion proteins were purified using glutathione-Sepharose (Pharmacia) from cell homogenates. The glutathione used to elute the proteins was removed from protein fractions by dialysis before using them for the gel shift assays or immunoprecipitation studies. cDNAs for human RARs and murine RXRs were generous gifts from Dr P. Chambon (INSERM, University Louis Pasteur, Strasbourg, France).<sup>24-27</sup>

Treatment of cells with retinoids. BAECs were isolated and grown in a minimal essential medium (aMEM) containing 10% newborn calf serum (Hyclone Laboratories, Logan, UT). Human aortic endothelial cells were purchased from Kurabo Biomedical Business (Osaka, Japan) and maintained in attached Humedia-EG2 medium. After the cells were grown to confluence, the cultures were rinsed with phosphate-buffered saline (PBS), pH 7.4, and incubated in either serum-free aMEM containing 0.1% bovine serum albumin (aMEM-BSA) or Humedia-EG2 medium containing 50 µmol/L L-ascorbic acid (Sigma), respectively, plus either 0.5% ethanol or various concentrations of retinoids. At the indicated time, the medium was aspirated, the cultures were washed with PBS, and (1) lysed with guanidium isothiocyanate solution and stored at  $-80^{\circ}$ C until isolation of RNA, (2) lysed with 0.5% Triton X-100 in 0.1 mol/L Tris-HCl, pH 8.1, and stored at -20°C until assay of cellular PA levels, or (3) lysed with 0.6% NP-40 solution and stored at -80°C until the preparation of nuclear extracts.

Isolation of RNA and Northern blot analysis. Total RNA was extracted from the cells using the acid guanidinium isothiocyanatephenol-chloroform extraction method.28 Each RNA (20 µg) was separated through 1% agarose-formaldehyde gel electrophoresis and transferred to the Biodyne A nylon membranes (Pall Biosupport, Port Washington, NY) according to the published protocols.<sup>29</sup> Membranes were hybridized with cDNA probes for either human RARa, RARB, or RAR $\gamma$ ; mouse RXR $\alpha$ , RXR $\beta$ , or RXR $\gamma$ ; or bovine uPA (a gift from Dr Wolf-Dieter Schleuning, Research Laboratories of Schering AG, Berlin, Germany)14 and were rehybridized with a probe for chicken glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The cDNA probes were labeled with  $[\alpha^{-32}P]dCTP$  (Du Pont, Wilmington, DE) via random priming using the kit (Boehringer Mannheim, Mannheim, Germany). After hybridization for 1 hour at 68°C using QuickHyb reagent (Stratagene, La Jolla, CA), blots were washed twice with 2× SSC, 0.1% sodium dodecyl sulfate (SDS) at room temperature for 15 minutes. The final wash was performed with 0.1× SSC, 0.1% SDS at 65°C for 30 minutes. For rehybridizations, blots were washed twice in  $0.1 \times$  SSC, 0.1% SDS at 97°C for 15 minutes and stripped. Autoradiography was performed using a Fujix BAS 2,000 Bio-imaging analyzer (Fuji Photo-Film, Tokyo, Japan). Each band was scanned, and the signal intensity was normalized to that obtained with GAPDH.

Assay of cellular PA activity. The levels of cellular PA activity were measured using the chromogenic substrate S-2403, as described previously,<sup>11</sup> and expressed as urokinase units per milligram of protein in the sample. Protein concentration was measured by BCA (Pierce, Rockford, IL) assay using BSA as the standard.

Transient transfection and luciferase assay. BAECs were seeded and grown in 35-mm dishes using phenol-red free  $\alpha$ MEM supplemented with 10% newborn calf serum until approximately 70% confluence on the day of the transfection. The cultures were rinsed with PBS and the cells were cotransfected using Lipofectamine Plus reagent (GIBCO BRL Life Technologies, Inc, Rockville, MD) in 1 mL of serum-free medium containing a reporter plasmid plus RAR and/or RXR expressing vectors (250 ng each/dish), along with pRL-CMV (*Renilla* luciferase, 100 ng/dish; Promega) as an internal standard to normalize transfection efficiency. Total DNA transfected was always adjusted to 1.225 µg/dish with empty pSG5 vector. After 4 hours of incubation, the cultures were overlaid with an additional 1 mL of medium containing 20% newborn calf serum and further incubated for 24 hours. The cells were then washed with PBS and treated or untreated with 1 µmol/L atRA or 9cRA for an additional 12 hours in serum-free medium. Thereafter, cell lysates were prepared by scraping cells into 120 µL of lysis buffer, and the luciferase activity of each cell lysate was measured using the Dual-Luciferase Reporter Assay System (Promega). Changes in firefly luciferase activity were calculated and plotted after normalization with changes in *Renilla* luciferase activity in the same sample. The uPA promoter-luciferase expressing vector, pGL2-2350, contains the human uPA promoter (-2345 to +32)<sup>30</sup> cloned into the *Kpn I/Bgl* II site of pGL2-Basic (Promega). Its deletion mutant,

measured using the Dual-Luciferase Reporter Assay System (Promega). Changes in firefly luciferase activity were calculated and plotted after normalization with changes in Renilla luciferase activity in the same sample. The uPA promoter-luciferase expressing vector, pGL2-2350, contains the human uPA promoter  $(-2345 \text{ to } +32)^{30}$  cloned into the Kpn I/Bgl II site of pGL2-Basic (Promega). Its deletion mutant, pGL2-GC, containing the first 65 bp and GC box and TATA box region (-2345 to -2280 and -91 to +32, respectively) was constructed by digestion of pGL2-2350 with Tth111I and Blp I, followed by blunting and religation. Another deletion mutant, pGL2- $\Delta$ GC, which contains uPA promoter devoid of the GC box region, was constructed by ligation of the pGL2 vector containing the TATA box (-28 to + 32) with the uPA promoter fragment deficient in the GC and TATA boxes (-2345 to -71). The TATA box-containing vector was prepared by digestion of pGL2-GC with Apa I, blunt-ending of the DNA, and successive digestion with Kpn I. The uPA promoter fragment deficient in the GC and TATA boxes was the Kpn I-fragment of a polymerase chain reaction (PCR) product that used pGL2-2350 as template. The following primers were used to generate this product: sense primer (based on the vector sequence located upstream of the cloning site in pGL2 vector), CTTCCCTTCCTTCTCG CCAC; and antisense primer (based on a gene-specific sequence corresponding to -71 to -91 of the uPA promoter), TCCCCTGTCTTGCAGCGCTCA. The DR5-luciferase reporter plasmid, pGL3-DR5, was constructed by insertion of DR5 globin promoter fragment (a gift from Dr S. Kato, Tokyo University, Tokyo, Japan)<sup>31</sup> into the Kpn I/Bgl II site of pGL3-Basic (Promega). Sp1-Gal4 expressing vector, which contains Sp1 fused with DNA binding domain of yeast Gal4 protein, and its reporter plasmid Gal4-UAS fused to luciferase, were kindly supplied from Dr S.L. Friedman (Mount Sinai Medical Center, New York, NY).<sup>32,33</sup> The Sp1 expression vector, pCIneo-Sp1, was constructed as follows. Human Sp1 cDNA, obtained from pSp1-778C (a gift from Dr J.T. Kadonaga, UCSD, San Diego, CA),<sup>34</sup> was subcloned first into Not I/HindIII site of pPROEX-HTb vector (GIBCO BRL), then into Spe I/HindII site of pBluescript SK II (+) (Stratagene), and finally into the Xba I/Acc I site of pCIneo mammalian expression vector (Promega).

Preparation of nuclear extracts and gel shift assay. Nuclear extracts were prepared in the following manner. Cells were detached from dishes, washed with Tris-buffered saline, and resuspended in ice-cold 10 mmol/L HEPES, pH 7.9, containing 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L dithiothreitol, and 0.5 mmol/L phenylmethylsulfonyl fluoride. After being incubated on ice for 15 minutes, cells were ruptured in the presence of 0.6% Nonidet NP-40, and the nuclear fraction was collected by centrifugation at 15,000g for 30 seconds at 4°C. Nuclei were lysed by shearing through a 27-gauge needle in ice-cold 50 mmol/L Tris-HCl, pH 8, containing 150 mmol/L NaCl, 5 mmol/L 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS; Sigma), and the Complete protease inhibitor cocktail (Boehringer Mannheim), and nuclear extracts were obtained as supernatants after centrifugation at 105,000g for 1 hour at 4°C. The protein concentrations were determined by BCA assays. Oligonucleotides corresponding to uPA GC box (-63 to -32), its mutant (sequences presented in Fig 4B), and consensus GC box (ATTCGATC-were synthesized, double-stranded, and end-labeled with  $[\gamma^{-32}P]ATP$  by T4 polynucleotide kinase using the kit from Boehringer Mannheim. For binding reactions, either 1 µg of nuclear proteins or 10 to 20 ng of purified Sp1 (Promega) were preincubated with or without 200 ng of purified RAR-GST and/or RXR-GST for 15 minutes on ice in the absence and presence of unlabeled oligonucleotides, and then 40 fmol of labeled oligonucleotide (10,000 µCi/mol) was added in the presence of 1 µg of dI-dC (Pharmacia) in 20 to 40 µL of binding buffer (20 mmol/L HEPES, pH 7.4, containing 1 mmol/L MgCl<sub>2</sub>, 10 µmol/L ZnSO<sub>4</sub>, 20 mmol/L KCl, and 8% glycerol). The reaction mixture was incubated for 15 minutes on ice and separated on a 4% polyacrylamide gel at 4°C. The gel was dried and exposed on films for a Fujix BAS 2,000 Bio-imaging analyzer (Fuji Photo-Film).

Immunoprecipitation and Western blotting. After a preincubation of 100 ng of Sp1 with 200 ng of each of RARs-and/or RXRs-GST proteins in PBS or in nuclear extract for 2 hours on ice, samples were combined with either anti-RARy antibody, M-454 (final concentration, 10 µg/mL; Santa Cruz Biotechnology), which uniformly recognizes three subtypes of RARs, or anti-RXR $\alpha$  antibody,  $\Delta N$  197 (final concentration, 10 µg/mL; Santa Cruz Biotechnology), which uniformly recognizes three subtypes of RXRs, and were incubated for 2 hours at 4°C or overnight on a rotating mixer. Protein A-Sepharose beads (Pharmacia) were then added and the samples were incubated for another 2 hours at the same temperature. The beads were then washed three times with PBS containing 0.05% Tween 20, and immunoprecipitated proteins were eluted into 4× reducing sample buffer for SDSpolyacrylamide gel electrophoresis (SDS-PAGE) and subjected to electrophoresis. Western blotting was performed using rabbit polyclonal anti-Sp1 antibody, PEP2 (final concentration, 1 µg/mL; Santa Cruz Biotechnology) as described previously,11 except that peroxidaseconjugated protein A (1/2,000 dilution; Sigma) was used instead of peroxidase-conjugated second antibody. Protein bands were visualized using the Amersham ECL system (Amersham, Buckinghamshire, UK).

GST fusion protein interaction assay. The [35S]methionineradiolabeled Sp1 protein was prepared by in vitro translation reaction using the TNT T7 system (Promega) according to the manufacturer's instructions. GST fusion proteins were mixed with glutathione-Sepharose 4B beads (Pharmacia) for 2 hours at 4°C in binding buffer (50 mmol/L Tris-HCl, pH 7.6, containing 50 mmol/L NaCl, 0.02% Tween 20, 0.02% BSA, and the Complete protease inhibitor cocktail). The glutathione beads, preincubated with RARa-GST, were washed three times with binding buffer and further incubated for 30 minutes at 4°C with [35S]methionine-radiolabeled Sp1 present in 15 µL of the reaction mixture after in vitro translation reaction, in a final volume of 300  $\mu$ L with the binding buffer. After washing five times with the washing buffer (50 mmol/L Tris-HCl, pH 7.6, containing 150 mmol/L NaCl, 0.02% Tween 20, and the Complete protease inhibitor cocktail), the bound proteins were eluted into  $4 \times$  reducing sample buffer for SDS-PAGE and subjected to electrophoresis followed by fluorography.

Statistics. Each number in the figures represents the average  $\pm$  SD (n = 3).

#### RESULTS

Induction of uPA through RAR. To analyze the molecular mechanism underlying the RA regulation of uPA transcription in endothelial cells, we first investigated whether RARs and/or RXRs might be involved. As seen in Fig 1A, upon stimulation with atRA, the expression of RAR $\alpha$  increased significantly along with a strong and transient induction of RAR $\beta$ , consistent with previous findings in other cell types.<sup>1,3,10,35</sup> Although RAR $\gamma$  decreased until 9 hours, the sum of the three RAR isoforms increased. In contrast, such a distinctive increase was not observed for RXRs, of which RXR $\alpha$  was the major species. The induction of uPA concurred with the increase of RAR $\alpha$  and RAR $\beta$ , whereas this induction did not occur when protein

synthesis was inhibited by cycloheximide (Fig 1B). RA stimulation did not alter the degradation rate of uPA mRNA after actinomycin D treatment, suggesting that RA did not significantly stabilize uPA mRNA (Fig 1C). A similar induction of uPA and RAR was observed in human aortic endothelial cells (Fig 1D). These results imply that the induction of uPA mRNA by RA is due to upregulation of uPA gene expression, which is dependent on new protein synthesis, and might be promoted by RARs, initially in particular by RAR $\alpha$ . To address the role of RARs, we examined the effect of subtype-specific agonists and antagonists (Fig 2). The agonists and antagonists used here have different receptor selectivities and can bind to and transactivate either RARs or RXRs or one of receptor subtypes (eg,  $\alpha$ ,  $\beta$ , or  $\gamma$ ).<sup>16-23</sup> Agonists capable of binding to and activating RAR $\alpha$ enhanced cellular PA levels almost identically (Fig 2A, panels a through d), whereas RAR<sub>β</sub>- or RAR<sub>γ</sub>-selective agonists showed a much weaker effect (Fig 2A, panels e and f, respectively). RXR-selective agonists administered alone were not effective (Fig 2A, panels g and h) and weakly inhibited uPA induction when combined with atRA (Fig 2A, panel i). The enhancement of cellular PA levels by atRA, Ch55, and Am580 was abolished by both the RAR $\alpha$ - and RAR $\beta$ -selective antagonists (Fig 2B). The specificities of the agonists and antagonists to discriminate RARs and RXRs from each other are strict, whereas those to discriminate each receptor subtype are relatively low (ie, 10-to 100-fold specific). So, these data suggest the involvement of RARs in uPA induction. To confirm the involvement of RARs in uPA transcription, transfection studies were performed with the uPA promoter-luciferase and RARs and/or RXRs expressing vectors (Fig 3A). Luciferase activity was enhanced 1.2-fold after treatment with atRA (sample 2). A significant increase ( $\sim$ 3-fold) was induced when cells were cotransfected with either RARa or RXRa (samples 3 and 5, respectively). Their effects were dose-dependent, and a similar effect was obtained with other isoforms (data not shown). Cotransfection with RAR $\alpha$  plus RXR $\alpha$  gave the largest increase (~9-fold; sample 7). Interestingly, these enhancing effects were not dependent on the presence of ligands (samples 4, 6, 8, and 9), although ligand dependence was observed in a parallel experiment in which DR5-luciferase was used as reporter (Fig 3B). Collectively, the above-noted results suggest that RA causes induction of RARa as well as RARB in endothelial cells, which leads to enhanced uPA transcription with the help of RXRs.

Involvement of Sp1 in RA induction of uPA. Computer analyses have shown that the uPA promoter used for the reporter assays does not contain any hitherto known RAREs, suggesting that RARs and or RXRs must transactivate the uPA promoter by a unique mechanism such as the interaction between RARs/ RXRs and other transcription factors. Recently, Safe et al have reported that estrogen receptor, another member of the nuclear hormone receptor super family, physically interacts with the ubiquitous transcription factor Sp1 and regulates the transactivation of its target genes.<sup>36,37</sup> We noticed that promoters of RA-inducible genes, including uPA, uPA receptor, and transglutaminase, contain GC boxes,<sup>30,38,39</sup> the cognate binding motif for Sp1.40 Therefore, we hypothesized that RARs/RXRs might also physically interact with Sp1 and regulate transactivation of uPA promoter. To explore this idea, we first examined whether Sp1 might be involved in the enhancing effect of RAR/RXR on



Fig 1. Induction of uPA and RARs by RA in endothelial cells. (A) Cell lysates were prepared from confluent BAEC cultures after the cultures had been incubated in  $\alpha$ MEM-BSA with 1  $\mu$ mol/L atRA for varying lengths of time. Total RNA was isolated from cell lysates, and the changes in uPA mRNA levels as well as RARs and RXRs mRNA levels were assessed by Northern blotting as described in Materials and Methods. (B) After BAECs were treated for the indicated times with 1  $\mu$ mol/L atRA in the absence or presence of 6  $\mu$ g/mL cycloheximide (CHX), changes in uPA mRNA levels were determined by Northern blotting. (C) After exposure to either vehicle or 1  $\mu$ mol/L atRA for 12 hours, BAECs were treated for the indicated times with 1  $\mu$ g/mL actinomycin D. The rate of disappearance of uPA mRNA was determined by Northern blotting. Because mRNA for GAPDH also decreased along with incubation with actinomycin D, we presented ethidium bromide-labeled 28S RNA as internal. (D) Northern analyses were performed using total RNA isolated from human aortic endothelial cells treated with 1  $\mu$ mol/L atRA for 12 hours.

uPA promoter transactivation. We used three different uPA promoter-luciferase constructs, including wild-type uPA promoter (pUK-Luc) or its mutants, either containing only GC and TATA boxes (pUK GC-Luc) or deficient in GC boxes (pUK  $\Delta$ GC-Luc). As shown in Fig 4A, the basal activities of pUK GC-Luc (sample 4) and pUK  $\Delta$ GC-Luc (sample 7) were, respectively, 93% and 27% of that of the wild-type pUK-Luc (sample 1), indicating the importance of GC box region for driving basal transactivation of uPA gene, as already reported

previously.<sup>30</sup> Transfection with RAR $\alpha$ /RXR $\alpha$  uniformly enhanced the transactivation of these three constructs, suggesting a potential existence of RAR/RXR responsible element(s) in both GC box and out-of-GC box regions within the uPA promoter. However, the majority of enhancing effects by RAR/RXR on pUK-Luc was reproduced in pUK GC-Luc (samples 5 and 6), implying that Sp1 might be involved in RA induction of uPA. We, therefore, examined this possibility by modifying Sp1 function in two ways. First, we found that the



Fig 2. Induction of uPA in BAECs by RAR-activating retinoids. Cellular PA levels were determined using a chromogenic substrate, S2403, after treatment of BAECs for 12 hours in aMEM-BSA either with (A) various concentrations of atRA (panel a), 9cRA (panel b), Ch55 (panel c), Am580 (panel d), CD2019 (panel e), CD666 (panel f), Ro47-5944 (panel g), and Ro25-7386 (panel h) or with a combination of various concentrations of atRA and 0.1 µmol/L Ro47-5944 (panel i) or (B) with 10-8 mol/L atRA (sample 2), Ch55 (sample 3), and Am580 (sample 4) in the absence or presence of 10<sup>-5</sup> mol/L Ro41-5253 (2) or LE135 (2). The specificity and characterization of each compound are described under Materials and Methods. Data are expressed as urokinase (UK) units (U) per milligram of protein in the sample. Each point represents the average  $\pm$  SD (n = 3).



Fig 3. Enhancement of uPA promoter transactivation activity by RAR $\alpha$  and RXR $\alpha$ . BAECs were cotransfected with UK promoter-luciferase (0.4  $\mu$ g/dish; A) or DR5-luciferase (0.4  $\mu$ g/dish; B) plus RAR $\alpha$  and/or RXR $\alpha$  expressing vectors (250 ng each/dish), along with pRL-CMV (*Renilla* luciferase, 100 ng/dish) as described in Materials and Methods. Total DNA transfected was adjusted to 1.225  $\mu$ g/dish with pSG5. The next day of transfection, the cells were treated or untreated with 1  $\mu$ mol/L atRA or 9cRA for 12 hours. Luciferase activity of each cell was measured using the Dual-Luciferase Reporter Assay System, and changes in firefly luciferase activity were calculated and plotted after normalization to *Renilla* luciferase activity. Sample 1, reporter only; sample 2, atRA; sample 3, RAR $\alpha$ ; sample 4, RAR $\alpha$  + atRA; sample 5, RXR $\alpha$ ; sample 6, RXR $\alpha$  + 9cRA; sample 7, RAR $\alpha$  and RXR $\alpha$ ; sample 8, RAR $\alpha$  and RXR $\alpha$  + atRA; sample 9, RAR $\alpha$  and RXR $\alpha$  + 9cRA. Each number represents the average ± SD (n = 3). Each similar experiment was repeated three times and representative results are shown here.

Sp1 decoy, a 32-mer oligonucleotide, the sequence of which was derived from the uPA GC box, dose-dependently reduced the induction of uPA levels (Fig 4B, curve b), whereas an oligonucleotide containing the mutated Sp1 site had no effect (Fig 4B, curve a). The action of the Sp1 decoy was specific. It did not block the binding of other transcription factors, including RAR, and did not influence cell viability (data not shown). A similar suppression was obtained when cells were treated with mithramycin (Fig 4C, curve b), a specific inhibitor of the binding of Sp1 to the GC box (Fig 4D).<sup>41,43</sup> The concentration of mithramycin used under the current experimental condition was not toxic to the cells, and the specificity of mithramycin has been ensured in the previous report.<sup>41,43</sup> Collectively, these results suggest that RA induction of uPA is dependent on Sp1 in addition to RARs/RXRs.

*Physical interaction between RARs/RXRs and Sp1*. We next explored whether RARs/RXRs and Sp1 would interact physically. Figure 5A shows the results of immunoprecipitation studies. Sp1 was coprecipitated with either anti-RAR or RXR antibody, only in the presence of RAR $\alpha$  (lane 4) or RXR $\alpha$  (lane 5), but not in their absence (lanes 6 and 7), suggesting a physical interaction between RAR $\alpha$ /RXR $\alpha$  and Sp1. The physical interaction was also observed for <sup>35</sup>S-labeled Sp1 in reticulocyte lysates incubated with RAR $\alpha$ -GST (Fig 5B) as well as for Sp1 incubated with RAR/RXR present in BAEC nuclear extracts (Fig 5C). The physical interaction between RAR/RXR and Sp1 was further supported by the results of the mammalian twohybrid assays (Fig 5D). Transactivation by Sp1 of Gal4-UASluciferase was potentiated by cotransfection with RAR $\alpha$  and/or RXR $\alpha$  (samples 3, 5, and 7), suggesting a direct interaction between RAR $\alpha$ /RXR $\alpha$  with Sp1 in vivo. Again, in this assay, obvious ligand dependence was not observed for RAR $\alpha$  (sample 4). However, RXR $\alpha$  alone or RAR $\alpha$ /RXR $\alpha$  showed some ligand dependence (samples 6, 8, and 9). Similar results were obtained for other subtypes of RARs/RXRs (data not shown).

Using gel shift assays, we next examined whether the direct interaction between RAR/RXR and Sp1 affected the ability of Sp1 to bind to DNA. We tested the effect of RAR $\alpha$  on the binding of various amounts of Sp1 to both the uPA GC box and consensus GC box. As shown in Fig 6A, RAR $\alpha$  potentiated the binding of Sp1 to both GC box sequences. The binding of Sp1 to both GC box sequences. The binding of Sp1 to these GC boxes was dose-dependent and drew a sigmoid curve, and RAR $\alpha$  functioned to shift this curve toward lower concentration range. Namely, when the basal Sp1 (DNA binding) activity was low, the potentiating effect became large, whereas when the basal activity was high, the potentiating effect was small. A similar potentiating effect was obtained with RXR $\alpha$  administered either alone or in combination with RAR $\alpha$  (Fig 6B, lanes 7 and 9). RAR $\alpha$  and RXR $\alpha$  either alone or in combination did not bind to the uPA GC box (Fig 6B, lanes 4, 6,



Fig 4. Involvement of Sp1 in RA induction of uPA. (A) Promoter assay. Transfection study was performed as described before using wild-type pUK-luciferase (pUK-Luc, samples 1 through 3), pUK GC box-luciferase (pUK GC-Luc, samples 4 through 6), and pUK-luciferase deficient in GC box (pUK  $\Delta$ GC-Luc, samples 7 through 9). Data are expressed as the relative luciferase activity compared with the activity of pUK-Luc cotransfected with empty pSG5 and untreated with 9cRA (sample 1). Samples 1, 4, and 7, reporter only; samples 2, 5, and 8, RAR $\alpha$  and RXR $\alpha$ ; samples 3, 6, and 9, RAR $\alpha$  and RXR $\alpha$  + 9cRA. (B) Transcription factor decoy experiments. After BAECs were transfected with various amounts of Sp1 decoy or its mutant, whose sequences are presented above the illustration, the cultures were incubated either with vehicle or with 1  $\mu$ mol/L atRA for 12 hours, cell lysates were prepared, and cellular PA levels were determined. Curves a and b, RA-treated cells; curves c and d, unstimulated cells. Curves a and d, mutant oligo; curves b and c, Sp1 decoy. (C) Cellular PA levels were determined after treatment of BAEC cultures with various concentrations of atRA for 12 hours in the absence (curve a) or presence (curve b) of 10 nmol/L mithramycin. For (A) through (C), the results are presented by the average ± SD (n = 3). Each similar experiment was repeated three times and representative results are shown here. (D) After treatment of BAECs with 1  $\mu$ mol/L atRA for 12 hours in the absence (lane 1) or presence (lane 2) of 10 nmol/L mithramycin, nuclear extracts were prepared and Sp1 binding to uPA GC box was determined by gel shift assays as described in Materials and Methods.

INDUCTION OF uPA THROUGH RAR-Sp1 INTERACTION



Fig 5. Physical interaction between RARa/RXRa and Sp1. (A) After the mixture of Sp1 plus either RARa or RXRa was incubated, respectively, with anti-RAR or RXR antibody at 4°C for 2 hours, proteins were precipitated with protein A-Sepharose, eluted, and analyzed by Western blotting with anti-Sp1 antibody. Lanes 1 through 3, pure proteins; lane 1, Sp1; lane 2, RARa; lane 3, RXRa. Lanes 4 through 7, proteins precipitated with anti-RAR or RXR antibody; lane 4, Sp1 preincubated together with RARa and precipitated with anti-RAR antibody; lane 5, Sp1 preincubated together with RXRa and precipitated with anti-RXR antibody; lane 6, Sp1 incubated with anti-RAR antibody without RARa; lane 7, Sp1 incubated with anti-RXR antibody without RXRa. (B) 35S-labeled Sp1 protein generated by in vitro translation reaction was incubated with GST or RARα-GST immobilized on glutathione-Sepharose beads. After extensive washings, the bound proteins were eluted and subjected to SDS-PAGE followed by autoradiography. Lane 1 input (0.5 µL of the total reaction mixture); lane 2, proteins bound to GST; lane 3, proteins bound to RAR<sub>α-GST.</sub> (C) After the mixture of Sp1 and RAR<sub>α</sub>/RXR<sub>α</sub> was incubated with nonimmune antibody or anti-RXR antibody in BAEC nuclear extracts at 4°C overnight, proteins were precipitated with protein A-Sepharose, eluted, and analyzed by Western blotting with anti-Sp1 antibody. Lane 1, pure Sp1; lane 2, proteins precipitated with nonimmune (NI) antibody; lane 3, proteins precipitated with anti-RXR antibody. (D) BAECs were cotransfected with a combination of Sp1-Gal4 expressing vector (0.125 µg/dish) and Gal4-UAS-luciferase (0.5 µg/dish), plus RARα and/or RXRa expressing vectors (250 ng each/dish), along with pRL-CMV (100 ng/dish; Promega) as described before. The day after transfection, the cells were treated or untreated with 1 µmol/L atRA or 9cRA for 12 hours. Luciferase activity of each cell was measured, and relative changes in firefly luciferase activity were plotted after normalization to Renilla luciferase activity. Sample 1, reporter only; sample 2, atRA; sample 3, RARa; sample 4, RARa + atRA; sample 5, RXRa; sample 6, RXRa + 9cRA; sample 7, RARa and RXRa; sample 8, RARa and RXRa + atRA; sample 9, RAR $\alpha$  and RXR $\alpha$  + 9cRA. Each number represents the average ± SD (n = 3). A similar experiment was repeated three times and representative results are shown here.





Fig 6. Potentiation of Sp1 binding to uPA GC box by RAR $\alpha$  and/or RXR $\alpha$ . (A) After Sp1 (10 to 20 ng) was preincubated in the absence or presence of RAR $\alpha$ -GST (200 ng), the reaction mixture was incubated with <sup>32</sup>P-labeled uPA GC box or consensus GC box, and thereafter protein-DNA complexes were separated by a 4% polyacrylamide gel electrophoresis and visualized on an image analyzer. Odd numbers, Sp1 alone; even numbers, Sp1 plus RAR $\alpha$ . (B) Gel shift analyses were performed as before using both RARa-GST and RXRα-GST. Lane 1, Sp1 (10 ng) alone; lane 2, GST alone; lane 3, Sp1 plus GST; lane 4, RARα alone; lane 5, Sp1 plus RARα; lane 6, RXRα alone; lane 7, Sp1 plus RXRa; lane 8, RARa and RXRa; lane 9, Sp1 plus RARa/RXRa. (C) Control experiments. Lane 1, control (Sp1 [10 ng] plus RARa/RXRa); lane 2, + 20-fold excess of unlabeled oligonucleotide (cold); lane 3, + 50-fold excess of unlabeled oligonucleotide (cold); lane 4, + 0.5% ethanol (vehicle); lane 5, + 1 μmol/L atRA; lane 6, + 1 μmol/L 9cRA; lane 7, + nonimmune (NI) antibody (IgG); Iane 8, + anti-Sp1 IgG; Iane 9, + anti-RAR IgG; Iane 10, + anti-RXR IgG; lane 11, + both anti-RAR IgG and anti-RXR IgG. The final concentration of each antibody was 80 µg/mL.

12

+

and 8), suggesting that RAR/RXR binding to DNA is not required for exertion of synergism. The potentiating effect of RARa/RXRa on Sp1 binding was not influenced by adding atRA or 9cRA (Fig 6C, lanes 5 or 6). No RAR-Sp1 or RXR-Sp1 complex was detected, as judged from supershift experiments (Fig 6C, lanes 8 through 11). The detected band was supershifted with anti-Sp1 antibody (lane 8) but not with anti-RAR antibody and/or anti-RXR antibody (lanes 9 through 11), suggesting that the increased band detected does not contain RAR $\alpha$ /RXR $\alpha$ . We cannot explain this reason, but predict that probably affinity between RAR/RXR and Sp1 might be relatively weak compared with the interaction between RAR and RXR,1,2,44,45 as observed for association between RAR/RXR and coactivator or corepressor.4-7 Hence, although Sp1 bound to increased numbers of radiolabeled uPA GC box after physical interaction with RARa and/or RXRa, RAR-Sp1 and RXR-Sp1 associations could be disrupted during electrophoresis. In fact, when we performed the immunoprecipitation from the mixture containing RAR, Sp1, and radiolabeled uPA GC box oligonucleotide, we succeeded in detecting specific radioactivity in anti-



RAR antibody-precipitated fraction. This radioactivity represents a specific binding of Sp1 to uPA GC box, suggesting that RAR, Sp1, and radiolabeled uPA GC box may form complexes in solution. The potentiating effect on Sp1 binding was not observed when BSA was used instead of RARs/RXRs (data not shown). We observed a similar result when comparing the binding of endogenous Sp1 present in the nuclear extract of control versus RARs transfected cells (data not shown). Collectively, these results suggest that physical interaction between RARs/RXRs and Sp1 may potentiate Sp1 binding to the uPA GC box and enhance uPA transcription. Finally, we confirmed this potentiation by a cotransfection experiment. When transcriptional activity of the uPA promoter was enhanced about fivefold by transfection of either Sp1 or RAR $\alpha$ /RXR $\alpha$  alone, cotransfection of these resulted in a 17-fold increase in activity.

### DISCUSSION

First, we demonstrated that RARs potentiate transactivation of the uPA gene, which lacks a canonical RARE, with help of RXRs. Interestingly, this effect appeared to be ligandindependent, suggesting a novel underlying mechanism. In support of this idea, we next demonstrated that RARs/RXRs directly interact with Sp1 and enhance transactivation of the uPA promoter, at least in part, by potentiating the binding of Sp1 to the uPA GC box. The result shown in Fig 6A suggests that the effect of RAR/RXR we found is a more general effect on Sp1-mediated transcription. The result shown in Fig 3A is thought to reflect the synergism between endogenous Sp1 and transfected RARs/RXRs. We cannot explain the discrepancy in ligand dependency among different experimental settings, eg, reporter assays (Figs 3A and 4A; apparent independence), two-hybrid assays (Fig 5D; partial dependence), and gel shift assays (Fig 6C; apparent independence). If the ligandindependence of the RAR/RXR-Sp1 effect is genuine, then the question arises as to which factor is responsible for the RA-dependency in uPA induction by RA. One likely answer is that at the very least RA is needed to increase RARs in the cells, although there are many other possibilities. RAR/RXR may act predominantly to strengthen the weak Sp1 binding. Alternatively, RAR/RXR may act both increasing Sp1 binding and enhancing the transcription of Sp1. We predict that effects on DNA binding may be ligand independent, whereas effects on transactivation may be ligand dependent.

We demonstrated that RARa/RXRa enhanced the transactivation of the wild-type uPA promoter-luciferase construct approximately sixfold (Fig 4A) and that of Gal4-UASluciferase construct about 25- to 30-fold in the mammalian two-hybrid system (Fig 5D). This difference can be explained as follows. As can be seen in Fig 6A, the binding of Sp1 to the GC box is dose-dependent and draws a sigmoid curve, and RAR/ RXR function to shift this curve toward lower concentration range. Namely, when the basal Sp1 (DNA binding) activity is low, the potentiating effect becomes large, whereas when the basal activity is high, the potentiating effect is small. A similar theory can be said for reporter assays. The basal activity of the Gal4-UAS-luciferase is low, because, theoretically, only Gal4 fusion protein is able to transactivate this reporter gene. In contrast, the full-length uPA promoter-luciferase is transactivated to some extent by endogenous Sp1 as well as other transcription factors. Therefore, the potentiating effect of RAR/

RXR is more dominant in the former assays compared with the latter assays.

The three subtypes of RARs seem to share equivalent ability in terms of interacting with and potentiating Sp1. Therefore, the dominant function of each subtype may be determined by the nature of the subtype expressed at a particular time. Under the present conditions, endothelial cells expressed  $RAR\alpha$  and RAR $\gamma$  initially, whereas the expression of RAR $\alpha$  and RAR $\beta$ was dramatically increased upon stimulation. The results showing that the expression of RAR $\alpha$  and RAR $\beta$  increased and that specific antagonists of these factors blocked the induction of uPA indicate the participation of RAR $\alpha$  and RAR $\beta$ , but fail to elucidate a role for RAR $\gamma$ . Although the contribution of RAR $\gamma$ appeared to be minimal, judging by the results obtained using the RARy-selective agonist (Fig 2A, panel f), our data do not rule out the involvement of RAR $\gamma$  in this system, especially after 12 hours, when the expression of RAR $\alpha$  and RAR $\beta$  started to decrease, in contrast to the expression of RARy, which started to increase (Fig 1A). Complementary expression of RAR $\beta$  and RAR $\gamma$  has been reported in the developing mouse embryo.46-48 A similar argument can be raised about the role of RXRs. Although the expression of RXR $\alpha/\beta$  did not change as observed for RAR $\alpha/\beta$  (Fig 1A) and RXR-selective retinoids were ineffective in enhancing uPA expression by BAECs (Fig 2A, panels g through i), RXRs themselves were capable of interacting with (Fig 5) and potentiating Sp1 binding (Fig 6) and stimulating uPA transactivation (Fig 3), both alone and in combination with RARs. This discrepancy could be explained partly because RXR-selective retinoids were unable to induce RARs nor RXRs in BAEC cultures (data not shown). The involvement of RAR $\gamma$  and RXR $\alpha/\beta$  in our system could be verified by examining the effect of an RAR $\gamma$  or RXR $\alpha/\beta$ specific antagonist, if such molecules could be obtained. Recently, Piedrafita and Pfahl49 reported that specific degradation of Sp1 occurs in apoptic T cells after treatment with a relatively high concentration of RARy-specific retinoids, whereas RA showed no significant effect. Because we used RA on endothelial cells, our system is different.

The functional interaction between RARs/RXRs and Sp1 has previously been described for the RA induction of the retinolbinding protein gene.<sup>50</sup> However, in this case, RARs and Sp1 bind to the RARE and GC box, respectively, and function synergistically. On the other hand, a physical interaction between Sp1 and other members of the nuclear receptor family has been reported.<sup>36,37,51,52</sup> The current study provides an initial evidence that RARs/RXRs also physically and functionally interact with Sp1 and enhance its binding affinity for target DNA without any need for binding of RARs/RXRs to RARE. Although we found that RAR/RXR-Sp1 interaction occurs in a tube in the absence of ligands, we cannot exclude the possibility that physiological interaction was dependent on a low concentration of RA that we may not have been able to eliminate from the serum ( $<10^{-10}$  mol/L). It is also possible that endogenous RARs/RXRs require ligand to keep corepressors away and to associate with Sp1, whereas large numbers of exogenously transfected RARs/RXRs might be free from limited numbers of corepressors and therefore might not require a ligand.

Several important issues remain unresolved: (1) It might be possible that RAR/RXR-Sp1 interaction not only potentiates Sp1-mediated transcription, but also allows RAR/RXR to drive transcription by enabling binding to the GC box via Sp1. Figure 5D demonstrates RAR $\alpha$  and RXR $\alpha$  enhancement of the transcriptional activity of a chimeric transcription factor, Sp1-Gal4, suggesting that RAR/RXR alter the transactivation domain of Sp1 and/or bind to Sp1-activation domain and confer their transactivation activity. (2) We predict that RARs may act as allosteric effectors that change the conformation of Sp1. Thus, it will be important to determine the nature of the change in Sp1 structure induced by binding to RARs/RXRs that is responsible for increased binding to GC box. (3) It will also be important to elucidate whether other nuclear factors, including corepressors and coactivators, modulate the RAR/RXR-Sp1 interaction. (4) Finally, because functional repression of gene expression through interaction between RAR and AP-1, NF-IL6, or Myb has been reported, 53-55 one may ask whether the RAR/RXR-Sp1 interaction affects other transcription factors shown to be important for basal as well as induced transcription from the uPA gene, such as Egr-1, PEA3, NF-KB, CREB, UEF1-4, and AP-1.56-59 We are now trying to map the binding site(s) in both RAR and Sp1 molecules as the first step towards answering these questions.

### ACKNOWLEDGMENT

The authors thank F. Blasi and S.L. Friedman for helpful advice and critical reading of the manuscript; S. Michel, M. Klaus, W.-D. Schleuning, J.T. Kadonaga, S. Kato, and P. Chambon for reagents and constructs; and C. Iijima, M. Yoshizawa, and S. Hayashi for technical assistance.

#### REFERENCES

1. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10:940, 1996

2. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 83:841, 1995

3. Sucov HM, Murakami KK, Evans RM: Characterization of an autoregulated response element in the mouse retinoic acid receptor type  $\beta$  gene. Proc Natl Acad Sci USA 87:5392, 1990

4. Chen JD, Evans RM: A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454, 1995

5. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811, 1998

6. Oñate SA, Tsai SY, Tsai M-J, O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354, 1995

7. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG: The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677, 1997

8. Bachmann F: The plasminogen-plasmin enzyme system, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice (ed 3). Philadelphia, PA, Lippincott, 1994, p 1592

9. Hajjar KA, Nachman RL: The human endothelial cell plasmingenerating system, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice (ed 3). Philadelphia, PA, Lippincott, 1994, p 823

10. Imai S, Okuno M, Moriwaki H, Muto Y, Murakami K, Shudo K, Suzuki Y, Kojima S: 9,13-di-*cis*-retinoic acid induces the production of tPA and activation of latent TGF- $\beta$  via RAR $\alpha$  in a human liver stellate cell line, LI90. FEBS Lett 411:102, 1997

11. Kojima S, Inui T, Muramatsu H, Suzuki Y, Kadomatsu K, Yoshizawa M, Hirose S, Kimura T, Sakakibara S, Muramatsu T:

#### INDUCTION OF uPA THROUGH RAR-Sp1 INTERACTION

Dimerization of midkine by tissue transglutaminase and its functional implication. J Biol Chem 272:9410, 1997

12. Kojima S, Muramatsu H, Amanuma H, Muramatsu T: Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 270:9590, 1995

13. Kojima S, Nara K, Rifkin DB: Requirement for transglutaminase in the activation of latent transforming growth factor- $\beta$  in bovine endothelial cells. J Cell Biol 121:439, 1993

14. Krätzschmar J, Haendler B, Kojima S, Rifkin DB, Schleuning W-D: Bovine urokinase-type plasminogen activator and its receptor: Cloning and induction by retinoic acid. Gene 125:177, 1993

15. Okuno M, Moriwaki H, Imai S, Muto Y, Kawada N, Suzuki Y, Kojima S: Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF- $\beta$  in liver stellate cells. Hepatology 26:913, 1997

16. Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K: Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 31:2182, 1988

17. Kagechika H, Himi T, Namikawa K, Kawachi E, Hashimoto Y, Shudo K: Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids. J Med Chem 32:1098, 1989

18. Eyrolles L, Kagechika H, Kawachi E, Fukasawa H, Iijima T, Matsushima Y, Hashimoto Y, Shudo K: Retinobenzoic acids. 6. Retinoid antagonists with a heterocyclic ring. J Med Chem 37:1508, 1994

19. Gianni' M, Zanotta S, Terao M, Garattini S, Garattini E: Effects of synthetic retinoids and retinoic acid isomers on the expression of alkaline phosphatase in F9 teratocarcinoma cells. Biochem Biophys Res Commun 196:252, 1993

20. Bernard BA, Bernardon J-M, Delescluse C, Martin B, Lenoir M-C, Maignan J, Charpentier B, Pilgrim WR, Reichert U, Shroot B: Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor  $\gamma$ . Biochem Biophys Res Commun 186:977, 1992

21. Rusten LS, Dybedal I, Blomhoff HK, Blomhoff R, Smeland EB, Jacobsen SEW: The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34<sup>+</sup> erythroid progenitor cells. Blood 87:1728, 1996

22. Kanatani Y, Makishima M, Asahi K, Sakurai A, Takahashi N, Motoyoshi K, Nagata N, Honma Y: Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-*cis* retinoic acid. Biochim Biophys Acta 1359:71, 1997

23. Apfel C, Bauer F, Crettaz M, Forni L, Kamber M, Kaufmann F, Lemotte P, Pirson W, Klaus M: A retinoic acid receptor  $\alpha$  antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci USA 89:7129, 1992

24. Benbrook D, Lernhardt E, Pfahl M: A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature 333:669, 1988

25. Brand N, Petkovich M, Krust A, Chambon P, de Thé H, Marchio A, Tiollais P, Dejean A: Identification of a second human retinoic acid receptor. Nature 332:850, 1988

26. Krust A, Kastner P, Petkovich M, Zelent A, Chambon P: A third human retinoic acid receptor, hRAR-γ. Proc Natl Acad Sci USA 86:5310, 1989

27. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen J-Y, Staub A, Garnier J-M, Mader S, Chambon P: Purification, cloning, and RXR identity of the Hela cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 68:377, 1992

28. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987

29. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A

Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989

30. Verde P, Boast S, Franzè A, Robbiati F, Blasi F: An upstream enhancer and a negative element in the 5' flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 16:10699, 1988

31. Kato S, Sasaki H, Suzawa M, Masushige S, Tora L, Chambon P, Gronemeyer H: Widely spaced, directly repeated PuGGTCA elements act as promiscuous enhancers for different classes of nuclear receptors. Mol Cell Biol 15:5858, 1995

32. Gill G, Pascal E, Tseng ZH, Tjian R: A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAF<sub>II</sub>110 component of the *Drosophila* TFIID complex and mediates transcriptional activation. Proc Natl Acad Sci USA 91:192, 1994

 Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229, 1998

34. Kadonaga JT, Courey AJ, Ladika J, Tjian R: Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science 242:1566, 1988

35. Dey A, Minucci S, Ozato K: Ligand-dependent occupancy of the retinoic acid receptor  $\beta 2$  promoter in vivo. Mol Cell Biol 14:8191, 1994

36. Duan R, Porter W, Safe S: Estrogen-induced c-*fos* protooncogene expression in MCF-7 human breast cancer cells: Role of estrogen receptor Sp1 complex formation. Endocrinology 139:1981, 1998

37. Sun G, Porter W, Safe S: Estrogen-induced retinoic acid receptor  $\alpha 1$  gene expression: role of estrogen receptor-Sp1 complex. Mol Endocrinol 12:882, 1998

38. Soravia E, Grebe A, De Luca P, Helin K, Suh TT, Degen JL, Blasi F: A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood 86:624, 1995

39. Lu S, Saydak M, Gentile V, Stein JP, Davies PJA: Isolation and characterization of the human tissue transglutaminase gene promoter. J Biol Chem 270:9748, 1995

40. Dynan WS, Tjian R: Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell 32:669, 1983

41. Greenwel P, Inagaki Y, Hu W, Walsh M, Ramirez F: Sp1 is required for the early response of  $\alpha 2(I)$  collagen to transforming growth factor- $\beta 1$ . J Biol Chem 272:19738, 1997

42. Carpenter ML, Marks JN, Fox KR: DNA-sequence binding preference of the GC-selective ligand mithramycin. Deoxyribonuclease-I/deoxyribonuclease-II and hydroxy-radical footprinting at CCCG, CCGC, CCGC, GCCC and GGGG flanked by (AT)*n* and A*n*·T*n*. Eur J Biochem 215:561, 1993

43. Nehls MC, Brenner DA, Gruss H-J, Dierbach H, Mertelsmann R, Herrmann F: Mithramycin selectively inhibits collagen- $\alpha$ 1(I) gene expression in human fibroblast. J Clin Invest 92:2916, 1993

44. Rastinejad F, Perlmann T, Evans RM, Sigler PB: Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 375:203, 1995

45. Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D: Crystal structure of the RAR- $\gamma$  ligand-binding domain bound to all-*trans* retinoic acid. Nature 378:681, 1995

46. Dolle P, Ruberte E, Leroy P, Morris-Kay G, Chambon P: Retinoic acid receptors and cellular retinoid binding proteins. I. A systematic study of their differential pattern of transcription during mouse organogenesis. Development 110:1133, 1990

47. Ruberte E, Dolle P, Chambon P, Morris-Kay G: Retinoic acid receptors and cellular retinoid binding proteins. II. Their differential pattern of transcription during early morphogenesis in mouse embryos. Development 111:45, 1991

48. Ruberte E, Friederich V, Chambon P, and Morris-Kay G: Retinoic acid receptors and cellular retinoid binding proteins. III. Their

differential transcript distribution during mouse nervous system development. Development 118:267, 1993

49. Piedrafita FJ, Pfahl M: Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol 17:6348, 1997

50. Panariello L, Quadro L, Trematerra S, Colantuoni V: Identification of a novel retinoic acid response element in the promoter region of the retinol-binding protein gene. J Biol Chem 271:25524, 1996

51. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB: Progesterone regulates transcription of the p21<sup>WAF1</sup> cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273:10696, 1998

52. Rohr O, Aunis D, Schaeffer E: COUP-TF and Sp1 interact and cooperate in the transcriptional activation of the human immunodeficiency virus type 1 long terminal repeat in human microglial cells. J Biol Chem 272:31149, 1997

53. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S-C, Heyman RA, Rose DW, Glass CK, Rosenfeld MG: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403, 1996

54. Nagpal S, Cai J, Zheng T, Patel S, Masood R, Lin GY, Friant S,

Johnson A, Smith DL, Chandraratna RAS, Gill PS: Retinoid antagonism of NF-IL6: Insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mol Cell Biol 17:4159, 1997

55. Pfitzner E, Kirfel J, Becker P, Rolke A, Schüle R: Physical interaction between retinoic acid receptor and the oncoprotein Myb inhibits retinoic acid-dependent transactivation. Proc Natl Acad Sci USA 95:5539, 1998

56. Khachigian LM, Lindner V, Williams AJ, Collins T: Egr-1induced endothelial gene expression: A common theme in vascular injury. Science 271:1427, 1996

57. Berthelsen J, Vandekerkhove J, Blasi F: Purification and characterization of UEF3, a novel factor involved in the regulation of the urokinase and other AP-1 controlled promoters. J Biol Chem 271:3822, 1996

58. De Cesare D, Palazzolo M, Blasi F: Functional characterization of COM, a DNA region required for cooperation between AP-1 sites in urokinase gene transcription. Oncogene 13:2551, 1996

59. De Cesare D, Palazzolo M, Berthelsen J, Blasi F: Characterization of UEF-4, a DNA-binding protein required for transcriptional synergism between two AP-1 sites in the human urokinase enhancer. J Biol Chem 272:23921, 1997